Technologies for Vaccines for COVID-19


Steve Chamow

Tuesday, May 19th, 5-6:30pm PT / 8-9:30pm ET
# people have already signed up
This event is sold out, but if you sign up for the waitlist, we'll let you know if spots become available.
You're on the waitlist now!
Oops! Something went wrong while submitting the form. Please email us at to join the waitlist.
Technologies for Vaccines for COVID-19
No items found.


Dr. Steve Chamow is back by popular demand for an extended conversation on COVID-19 drug development. Event Description: Join Dr. Steve Chamow for a continuation of his first Speakeasy talk: What Does It Take to Develop a New Drug for COVID-19? In this extended conversation, Steve will dive deeper into the availability of technologies for therapeutics and vaccines. He’ll also share opportunities to shorten the timeline of clinical drug development during a public health emergency. Event Location: This event will take place online via Zoom, a free video-conferencing tool. New to Zoom? After you buy your ticket, you'll receive an email with step-by-step instructions on how to use it, and you'll be a pro in no time! Steve’s Bio: Dr. Steven Chamow has over 30 years of experience in biopharmaceutical product development. Since 2008, he has served as president of Chamow & Associates, Inc., a consulting group working with biotechnology companies to design and implement strategies to develop new therapeutic products. In his career, he has contributed to the development of three marketed biologics (Avastin, Natrecor, Vectibix). Prior to his current position, he was Senior Vice President, CMC, at Intradigm Corporation, a private biopharmaceutical company focused on developing RNAi therapeutics (acquired by Silence Therapeutics). Dr. Chamow was Vice President, Process Sciences, at Genitope Corporation and at Abgenix, Inc., (acquired by Amgen) where he built the company’s process sciences department and helped to lead the design and construction of Abgenix’ award-winning production facility in Fremont, CA (sold by Amgen to Boehringer-Ingelheim to become its first North American production facility). Before Abgenix, he served as Director of Biopharmaceutical Development at Scios, Inc. (acquired by J&J), and as a scientist and senior scientist in process development at Genentech, Inc. (acquired by Roche). Dr. Chamow was educated at the University of California (UC Santa Cruz, B.A. in biology; UC Davis, Ph.D. in biochemistry), and completed postdoctoral training at the National Institutes of Health in Bethesda, MD. He is author or co-author of more than 50 scientific publications and patents and co-editor of two books. About Speakeasy: Speakeasy offers intimate events with compelling speakers and performers online via Zoom. Learn more about Speakeasy, and check out a list of all of our events.

What to expect at this event